+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biopharmaceutical Contract Manufacturing Market by Type of Product, Scale of Operations, Expression System, Company Size, Biologics and Key Geographical Regions - Industry Trends and Global Forecast to 2030

  • ID: 5397780
  • Report
  • February 2021
  • Region: Global
  • 783 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Biomay
  • Educell
  • JHL Biotech
  • Ono Pharmaceutical
  • SIRION Biotech

Overview

The development pipelines of big biopharma companies are extensive and it is difficult for such players to carry out manufacturing operations using in house capacities. As a result, such companies often opt to outsource certain aspects of their production processes, predominantly drug substance manufacturing and aseptic filling. Therefore, there is a high demand for contract services from the aforementioned companies

- Senior Manager Strategic Marketing, a Germany-based Large sized CMO

Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are currently under clinical investigation, across the world. Given the evident benefits (including high efficacy, target specificity and favorable safety profiles) of biologics over small molecule drugs, the biopharma market is poised to witness continued and consistent growth over the next several years. However, biologics production is a complex and capital-intensive process fraught with a wide range of challenges. Some of key concerns of contemporary innovators include the rate of attrition of pipeline drugs/therapies, prolonged development timelines, complex molecular structure (which demand niche and specialized expertise), current facility limitations and capacity constraints, and safety and efficacy-related issues.

Given the technical and operational challenges outlined above, an increasing number of drug developers have demonstrated the preference to outsource various parts of their biologics manufacturing operations. The landscape of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) market, specifically those that claim to have biologics-related capabilities, features a mix of large, mid-sized and small companies. As a result of several mergers and acquisitions, the market is now fairly consolidated with a number of established players operating as one-stop-shops. Moreover, since the biopharmaceutical sector is amongst the most highly regulated industries in the world, biopharma CMOs, specifically those offering regulatory assistance, are perceived as attractive strategic partners (especially to the smaller developer companies). With outsourcing being increasingly accepted as a viable and beneficial business model within the biopharmaceutical industry, we anticipate the biologics manufacturing services market to grow at a steady pace in the coming years.

Scope of the Report

The “Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). 

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring an elaborate list of active CMOs, along with information on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of biologics manufactured (peptides/proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactor used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging. 
  • A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), and including an analysis based on the location of these facilities, highlighting key manufacturing hubs for biologics.  
  • Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as an informed future outlook. 
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs. 
  • A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes. 
  • A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug/therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics/drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the various biopharmaceutical based manufacturing initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation, types of biologics manufactured and type of product.
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of biologics, based on various parameters, such as the year the agreement was signed, type of agreement, focus area, types of biologics manufactured, therapeutic area and geographical regions. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during 2015-2020, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees and experience of the acquired company. 
  • A detailed analysis of the recent expansions undertaken (since 2015) by various service providers for augmenting their respective biopharma contract manufacturing service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion and new facility), types of biologics manufactured, geographical location of facility, and most active players (in terms of number of instances).
  • An analysis of the recent developments within the biopharmaceutical contract manufacturing industry, highlighting information on the funding and technology advancements related to biomanufacturing. 
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs/CDMOs) engaged in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical/clinical, commercial), company size (small, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, South Korea and Australia), Latin America, Middle East and North Africa). 
  • An informed estimate of the annual demand for biologics, taking into account the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry. 
  • A survey analysis featuring inputs solicited from various experts who are directly/indirectly involved in providing contract manufacturing services to biopharmaceutical developers.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs)), [B] types of expression systems used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large/very large), [E] types of biologics manufactured (antibody, vaccine, cell therapy and other biologics) and [F] key geographical regions (North America (the US, Canada), Europe (the UK, France, Germany, Italy and Spain), Asia (China, India and Australia), Latin America, Middle East and North Africa). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders (arranged in alphabetical order):

  • Andrea Conforto (Sales & Marketing, Bioservices Director, Olon)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Birgit Schwab (Senior Market Intelligence Manager, Rentschler Biotechnologie)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Claire Otjes (Marketing Manager, Batavia Biosciences)
  • David C Cunningham (Director Corporate Development, Goodwin Biotechnology) 
  • Dietmar Katinger(Chief Executive Officer, Polymun Scientific)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) 
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Kevin Daley (Market Director Pharmaceuticals, Novasep) 
  • Mark Wright (ex-Site Head, Grangemouth, Piramal Healthcare)
  • Max Rossetto (General Manager - Business Development, Luina Bio)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)
  • Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals) 
  • Sebastian Schuck (Director Global Business Development, WACKER BIOTECH Biotech) 
  • Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) 
  • Marco Schmeer (Project Manager, PlasmidFactory) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)
  • Tim Oldham (ex - Chief Executive Officer, Cell Therapies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Biomay
  • Educell
  • JHL Biotech
  • Ono Pharmaceutical
  • SIRION Biotech

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems for Biopharmaceuticals
3.3.1. Insect Expression Systems 
3.3.2. Mammalian Expression Systems
3.3.3. Microbial Expression Systems
3.3.3.1. Bacterial Expression Systems
3.3.3.2. Fungal Expression Systems
3.3.3.3. Yeast Expression Systems
3.3.4. Plant Expression Systems
3.3.5. Mammalian versus Microbial Expression Systems
3.4. Manufacturing Process of Biopharmaceuticals
3.4.1. Upstream Processing
3.4.2. Fermentation
3.4.3. Downstream Processing
3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
3.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
3.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations 
3.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
3.7. Key Considerations while Selecting a Contract Manufacturing Partner
3.8. Future Perspectives

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size 
4.2.3. Analysis by Location of Headquarters 
4.2.4. Analysis by Type of Product
4.2.5. Analysis by Types of Biologics Manufactured 
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Types of Expression Systems Used
4.2.8. Analysis by Type of Bioreactors 
4.2.9. Analysis by Mode of Operation of Bioreactors

5. MANUFACTURING FACILITIES OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOs)
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Overall Landscape of Biopharmaceutical Contract Manufacturing Facilities
5.3.1. Analysis by Type of Product
5.3.2. Analysis by Scale of Operation
5.3.3. Analysis by Type of Expression System Used
5.4. Biopharmaceutical Contract Manufacturing Facilities in North America
5.5. Biopharmaceutical Contract Manufacturing Facilities in Europe
5.6. Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
6.2.1. Impact of Current Political Situation
6.3. Leading Biopharmaceutical CMOs in North America
6.3.1. AGC Biologics
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.2.1. Process Development
6.3.1.2.2. cGMP Manufacturing
6.3.1.2.3. Quality and Regulatory
6.3.1.2.4. Process Validation
6.3.1.3. Financial Information
6.3.1.4. Manufacturing Facilities
6.3.1.5. Partnerships
6.3.1.6. Recent Developments
6.3.1.7. Future Outlook
6.3.2. Catalent (Catalent Pharma Solutions)
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.2.1. Cell Line Development
6.3.2.2.2. Manufacturing (Biomanufacturing)
6.3.2.2.3. ADCs and Bioconjugates Manufacturing
6.3.2.2.4. Biosimilars Development and Manufacturing
6.3.2.2.5. Proprietary Delivery and Fill / Finish Solutions
6.3.2.2.6. Analytical Services
6.3.2.3. Clinical Supply Services
6.3.2.4. Financial Information
6.3.2.5. Manufacturing Facilities
6.3.2.6. Partnerships
6.3.2.7. Recent Developments
6.3.2.8. Future Outlook
6.3.3. Cytiva (GE Healthcare) 
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.2.1. Biomanufacturing Services
6.3.3.2.2. Scientific Support
6.3.3.2.3. OptiRun Service Solutions
6.3.3.2.4. Instruments Qualification Services
6.3.3.3. Financial Information
6.3.3.4. Manufacturing Facilities
6.3.3.5. Partnerships
6.3.3.6. Recent Developments
6.3.3.7. Future Outlook
6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.2.1. Strain Development
6.3.4.2.2. Process Development
6.3.4.2.3. GMP Contract Manufacturing
6.3.4.2.4. Analytical Solutions
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Partnerships
6.3.4.6. Recent Developments
6.3.4.7. Future Outlook
6.3.5. KBI Biopharma
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.2.1. Process Development
6.3.5.2.2. Analytical Development
6.3.5.2.3. GMP Manufacturing
6.3.5.2.4. Clinical Cell Therapy Support
6.3.5.3. Manufacturing Facilities
6.3.5.4. Partnerships
6.3.5.5. Future Outlook
6.3.6. Patheon (acquired by Thermo Fisher Scientific) 
6.3.6.1 Company Overview
6.3.6.2. Service Portfolio
6.3.6.2.1. Biologics
6.3.6.2.1.1. Drug Substance
6.3.6.2.2. Analytical Services
6.3.6.2.3. Product Development
6.3.6.2.4. Commercial Product Supply
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Partnerships
6.3.6.6. Recent Developments
6.3.6.7. Future Outlook
6.3.7. Piramal Pharma Solutions 
6.3.7.1 Company Overview
6.3.7.2. Service Portfolio
6.3.7.2.1. Antibody Drug Conjugation Services
6.3.7.2.2. Other Services
6.3.7.3. Financial Information
6.3.7.4. Manufacturing Facilities
6.3.7.5. Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
7.2.1. EMA’s cGMP Regulations
7.3. Leading Biopharmaceutical CMOs in Europe
7.3.1. Boehringer Ingelheim BioXcellence
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.2.1. Process Development
7.3.1.2.1.1. Expression Systems
7.3.1.2.1.2. Upstream Technology
7.3.1.2.1.3. Downstream Technology
7.3.1.2.1.4. Other Process Development Services
7.3.1.2.2. Quality Assurance
7.3.1.2.3. Fill / Finish
7.3.1.3. Financial Information
7.3.1.4. Manufacturing Facilities
7.3.1.5. Partnerships
7.3.1.6. Recent Developments
7.3.1.7. Future Outlook
7.3.2. Lonza
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Manufacturing Services
7.3.2.4. Financial Information
7.3.2.5. Manufacturing Facilities
7.3.2.6. Partnerships
7.3.2.7. Recent Developments
7.3.2.8. Future Outlook
7.3.3. Novasep 
7.3.3.1 Company Overview
7.3.3.2. Service Portfolio
7.3.3.2.1. Services for Viruses and Viral Vectors
7.3.3.2.2. Services for Monoclonal Antibodies
7.3.3.2.3. Services for ADCs
7.3.3.2.4. Quality, Regulatory and Other Services
7.3.3.3. Financial Information
7.3.3.4. Manufacturing Facilities
7.3.3.5. Partnerships
7.3.3.6. Recent Developments
7.3.3.7. Future Outlook
7.3.4. Olon
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Manufacturing Facilities
7.3.4.4. Future Outlook
7.3.5. Rentschler Biopharma 
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.2.1. Bioprocess Development
7.3.5.2.2. Biomanufacturing Services
7.3.5.2.3. Other Services
7.3.5.3. Manufacturing Facilities
7.3.5.4. Partnerships
7.3.5.5. Recent Developments
7.3.5.6. Future Outlook
7.3.6. Sandoz
7.3.6.1. Company Overview
7.3.6.2. Service Portfolio
7.3.6.3. Financial Information
7.3.6.4. Future Outlook

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in China
8.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
8.2.2. Challenges Faced while Outsourcing to China
8.3. Leading Biopharmaceutical CMOs in China
8.3.1. WuXi AppTec (WuXi Biologics)
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Discovery Services
8.3.1.2.2. Development Services
8.3.1.2.3. Testing Services
8.3.1.2.4. Clinical Manufacturing Services
8.3.1.2.5. Fill / Finish Operations
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Partnerships
8.3.1.6. Recent Developments
8.3.1.7. Future Outlook
8.4. Biopharmaceutical Contract Manufacturing in India
8.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
8.4.2. Challenges Faced while Outsourcing to India
8.5. Leading Biopharmaceutical CMOs in India
8.5.1. Kemwell Biopharma 
8.5.1.1. Company Overview
8.5.1.2. Service Portfolio
8.5.1.2.1. Development Services for Biopharmaceuticals
8.5.1.2.2. Manufacturing Services for Biopharmaceuticals
8.5.1.3. Manufacturing Facilities
8.5.1.4. Partnerships
8.5.1.5. Recent Developments
8.5.1.6. Future Outlook
8.6. Biopharmaceutical Contract Manufacturing in Japan
8.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
8.7. Leading Biopharmaceutical CMOs in Japan
8.7.1. Minaris Regenerative Medicine
8.7.1.1. Company Overview
8.7.1.2. Service Portfolio
8.7.1.2.1. Manufacturing Development
8.7.1.2.2. GMP Manufacturing
8.7.1.3. Manufacturing Facilities
8.7.1.4. Recent Developments
8.7.1.5. Future Outlook
8.7.2. Takara Bio
8.7.2.1. Company Overview
8.7.2.2. Service Portfolio
8.7.2.3. Financial Information
8.7.2.4. Manufacturing Facilities
8.7.2.5. Future Outlook
8.8. Biopharmaceutical Contract Manufacturing in South Korea
8.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
8.9. Leading Biopharmaceutical CMOs in South Korea
8.9.1. Celltrion
8.9.1.1. Company Overview
8.9.1.2. Service Portfolio
8.9.1.3. Financial Information
8.9.1.4. Manufacturing Facilities
8.9.1.5. Future Outlook
8.9.2. Samsung BioLogics
8.9.2.1. Company Overview
8.9.2.2. Service Portfolio
8.9.2.2.1. Process Development
8.9.2.2.2. Analytical Services
8.9.2.2.3. cGMP Manufacturing Services
8.9.2.2.4. Aseptic Fill / Finish
8.9.2.2.5. Quality Services
8.9.2.2.6. Other Services
8.9.2.3. Financial Information
8.9.2.4. Manufacturing Facilities
8.9.2.5. Partnerships
8.9.2.6. Recent Developments
8.9.2.7. Future Outlook
8.10. Biopharmaceutical Contract Manufacturing in Australia
8.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
8.11. Leading Biopharmaceutical CMOs in Australia
8.11.1. Cell Therapies
8.11.1.1. Company Overview
8.11.1.2. Service Portfolio
8.11.1.3. Manufacturing Facilities
8.11.1.4. Partnerships
8.11.1.5. Future Outlook
8.11.2. Luina Bio
8.11.2.1. Company Overview
8.11.2.2. Service Portfolio
8.11.2.2.1. Microbial Products
8.11.2.2.2. Vaccines
8.11.2.2.3. Support Services
8.11.2.2.4. Quality-related Services
8.11.2.3. Manufacturing Facilities
8.11.2.4. Partnerships
8.11.2.5. Recent Developments
8.11.2.6. Future Outlook

9. NICHE BIOPHARMACEUTICAL SECTORS
9.1. Chapter Overview
9.2. Bispecific Antibodies
9.2.1. Introduction
9.2.2. Pipeline Analysis
9.2.2.1. Bispecific Antibody Therapeutics: Clinical Pipeline
9.2.2.2. Bispecific Antibody Therapeutics: Early Stage Pipeline
9.2.2.3. Multivalent Drug Candidates
9.2.3. Analysis by Phase of Development
9.2.4. Analysis by Target Indication
9.2.5. Bispecific Antibody Therapeutics: List of Technology Providers
9.2.6. Key Manufacturing Considerations and Challenges
9.2.7. Contract Manufacturing Scenario
9.2.7.1. CMOs Offering Services for Bispecific Antibodies
9.3. Antibody Drug Conjugates (ADCs)
9.3.1. Components of ADCs
9.3.1.1. Antibody
9.3.1.2. Cytotoxin
9.3.1.3. Linker
9.3.2. Manufacturing Process
9.3.3. Pipeline Analysis
9.3.3.1. ADC Therapeutics: Clinical Pipeline
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Target Indication
9.3.6. Key Technology Players: Analysis by Number of ADC Therapeutics
9.3.7. Novel Drug Conjugates
9.3.8. Key Manufacturing Considerations and Challenges 
9.3.9. Contract Manufacturing Scenario
9.3.9.1. CMOs Offering Services for ADCs
9.4. Cell Therapies
9.4.1. Introduction
9.4.2. Current Market Landscape
9.4.3. Cell Therapy Manufacturing
9.4.3.1. Cell Therapy Manufacturing Models
9.4.3.1.1. Centralized Manufacturing
9.4.3.1.2. Decentralized Manufacturing
9.4.4. Key Manufacturing Considerations and Challenges
9.4.5. Factors Influencing Cell Therapy Manufacturing
9.4.5.1. Characterization
9.4.5.2. Cost of Goods
9.4.5.3. Automation of Cell Therapy Manufacturing
9.4.6. Analysis by Types of Cells Manufactured
9.4.7. Stem Cell Therapies: Analysis by Phase of Development
9.4.8. T-Cell Therapies: Analysis by Phase of Development
9.4.9. Contract Manufacturing Scenario
9.4.9.1. CMOs Offering Services for Cell Therapy
9.5. Gene Therapy
9.5.1. Gene Therapy Market: Pipeline Analysis
9.5.1.1. Analysis by Stage of Development
9.5.1.2. Analysis by Phase of Development
9.5.1.3. Analysis by Type of Vector Used
9.5.1.3.1. Clinical Pipeline
9.5.1.3.2. Preclinical Pipeline
9.5.1.4. Analysis by Target Indication
9.5.1.4.1. Clinical and Commercial Pipeline
9.5.1.4.1. Preclinical Pipeline
9.5.1.5. Analysis by Location of Manufacturing Facility
9.5.1.6 Analysis by Type of Viral Vector Used
9.5.2. Contract Manufacturing Scenario
9.5.2.1. CMOs Offering Services for Viral Vectors
9.6. Plasmid DNA 
9.6.1. Introduction
9.6.2. Analysis by Location of Manufacturing Facility
9.6.3. Contract Manufacturing Scenario
9.6.3.1. CMOs Offering Services for Plasmid DNA

10. CASE STUDY: OUTSOURCING OF BIOSIMILARS
10.1. Chapter Overview
10.2. Biosimilars: An Introduction
10.3. Biosimilars: Development Stages
10.4. Regulatory Requirements for Licensing of Biosimilars
10.5. Need for Outsourcing Biosimilar Development and Manufacturing 
10.6. Impact of Biosimilars on the Global Contract Manufacturing Market
10.6.1. Pipeline Analysis of Biosimilars, 2013 versus 2020
10.7. Biosimilars Contract Manufacturing Service Providers
10.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations 

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
11.1. Chapter Overview
11.2. Small Molecule and Large Molecule Drugs / Therapies
11.2.1. Comparison of General Characteristics
11.2.2. Comparison of Key Specifications
11.2.3. Comparison of Manufacturing Process
11.2.4. Comparison of Key Manufacturing Challenges

12. CASE STUDY: IN-HOUSE MANUFACTURING
12.1. Chapter Overview
12.2. In-House Manufacturing
12.2.1. Benefits Associated with In-House Manufacturing
12.2.2. Risks Associated with In-House Manufacturing
12.3. Outsourcing in the Biopharmaceutical Industry
12.3.1. Types of Outsourcing Partners
12.4. Manufacturing Approaches Used for Approved Biologics (2016-2020)
12.4.1. Approved Biologics: Analysis by Company Size and Type of Manufacturing Model Adopted
12.4.2. Approved Biologics: Analysis by Company Size and Types of Biologics 
12.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters 
13.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4
13.4. Conclusion

14. BIG PHARMA INITIATIVES 
14.1. Chapter Overview
14.2. List of Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Purpose of Initiative
14.2.4. Analysis by Type of Initiative
14.2.4.1. Analysis by Type of Partnership
14.2.4.2. Analysis by Type of Expansion
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis by Types of Biologics Manufactured
14.2.7. Analysis by Year of Initiative and Company
14.2.8. Analysis by Purpose of Initiative and Company
14.2.9. Analysis by Year and Type of Initiative
14.2.10. Analysis by Type of Region of Expansion and Company
14.2.11 Analysis by Types of Biologics Manufactured and Company
14.3. Competitive Benchmarking of Big Pharma Players
14.3.1. Harvey Ball Analysis: Big Pharma Investment Summary

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Biopharmaceutical Contract Manufacturing: List of Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Focus Area
15.3.4. Analysis by Focus Area and Type of Partnership Model Adopted
15.3.5. Analysis by Year and Type of Partnership Model Adopted
15.3.6. Analysis by Types of Biologics Manufactured
15.3.7. Analysis by Year and Types of Biologics Manufactured
15.3.8. Analysis by Types of Biologics Manufactured and Type of Partnership Model Adopted
15.3.9. Analysis by Types of Biologics Manufactured and Geography
15.3.10. Analysis by Therapeutic Area
15.3.11. Most Active Players: Analysis by Number of Partnerships
15.3.12. Regional Analysis
15.3.13. Local and Intracontinental Agreements

16. MERGERS AND ACQUISITIONS
16.1. Chapter Overview
16.2. Merger and Acquisition Models
16.3. Acquisition Models
16.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions 
16.4.1. Cumulative Year-wise Trend
16.4.2. Analysis by Type of Acquisition
16.4.3. Analysis by Geographical Activity
16.4.3.1. Mergers and Acquisitions: Continent-wise Distribution
16.4.3.2. Mergers and Acquisitions: Country-wise Distribution
16.4.4. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
16.4.5. Most Active Acquirers: Analysis by Number of Acquisitions
16.4.6 Analysis by Key Value Drivers
16.2.6.1. Analysis by Key Value Drivers and Year of Acquisition
16.2.6.2. Analysis by Key Value Drivers and Types of Biologics Manufactured
16.2.6.3. Analysis by Types of Biologics Manufactured
16.3. Key Acquisitions: Deal Multiples

17. RECENT EXPANSIONS
17.1. Chapter Overview
17.2. Biopharmaceutical Contract Manufacturing Market: Expansions
17.2.1. Cumulative Year-wise Distribution
17.2.2. Analysis by Purpose of Facility Expansion
17.2.3. Analysis by Year and Purpose of Expansion
17.2.4. Analysis by Types of Biologics Manufactured
17.2.5. Analysis by Types of Biologics Manufactured and Purpose of Expansion
17.2.6. Analysis by Location of Manufacturing Facility
17.2.7. Regional Analysis
17.2.8. Most Active Players: Analysis by Number of Recent Expansions
17.2.9. Analysis by Location of Headquarters and Purpose of Expansion
17.2.10. Facility Expansions: 2016-2018 and 2016-2020 Scenario

18. RECENT DEVELOPMENTS
18.1. Biopharmaceutical Contract Manufacturing Market: Funding Instances
18.2. Technological Advancements
18.2.1. Single Use Technology
18.2.2. Process Analytical Technology (PAT)
18.2.3. Continuous Processing
18.2.4. Quality by Design (QbD) in Bio-Processing
18.2.5. Modular / Podular Biopharma Facilities

19. CAPACITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Biopharmaceutical CMOs: Global Production Capacity
19.3.1. Analysis by Company Size 
19.3.2. Analysis by Type of Expression Systems Used
19.3.3. Analysis by Scale of Operation
19.3.4. Analysis by Region
19.3.4.1. Capacity Analysis: North America
19.3.4.2. Capacity Analysis: Europe
19.3.4.3. Capacity Analysis: Asia-Pacific
19.4. Conclusion

20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Overall Annual Demand for Biopharmaceuticals Market, 2020-2030
20.3.1. Analysis by Therapeutic Area
20.4. Relationship Between Annual Demand and Capacity
20.5. Demand for Emerging Novel Biologics
20.5.1. ADC Therapeutics: Overall Annual Demand
20.5.2. ADC Therapeutics: Demand and Supply Analysis
20.6. Global Demand for Cell Therapy Manufacturing

21. MARKET SIZING AND OPPORTUNITY SIZING
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Biopharmaceutical Contract Manufacturing Market, 2020-2030
21.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030
21.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030
21.3.3. Biopharmaceutical Contract Manufacturing Market for Others Manufacturing, 2020-2030
21.4. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Type of Expression Systems Used
21.5. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
21.6. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size
21.7. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured
21.8. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography
21.8.1. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030
21.8.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030
21.8.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030
21.8.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
21.8.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
21.8.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations
21.8.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
21.8.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations
21.8.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
21.8.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
21.8.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
21.8.1.11. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics
21.8.1.12. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines
21.8.1.13. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies
21.8.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030
21.8.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030
21.8.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030
21.8.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2020-2030
21.8.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030
21.8.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030
21.8.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030
21.8.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
21.8.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
21.8.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations
21.8.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
21.8.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations
21.8.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
21.8.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
21.8.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
21.8.2.15. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics
21.8.2.16. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines
21.8.2.17. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies
21.8.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030
21.8.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
21.8.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2020-2030
21.8.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030
21.8.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030
21.8.3.5. Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030
21.8.3.6. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations
21.8.3.7. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations
21.8.3.8. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations
21.8.3.9. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations
21.8.3.10. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Scale Operations
21.8.3.11. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies
21.8.3.12. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies
21.8.3.13. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Large / Very Large Companies
21.8.3.14. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics
21.8.3.15. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines
21.8.3.16. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies
21.8.4. Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030
21.8.5. Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030

22. SWOT ANALYSIS
22.1 Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Conclusion

23. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
23.1. Chapter Overview
23.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
23.3. Shift from One-time Contracts to Strategic Partnerships
23.4. Integration / Adoption of New and Innovative Technologies
23.4.1. Single use Bioreactors
23.4.2. Novel Bioprocess Techniques
23.4.3. Bioprocess Automation
23.5. Focus on Niche Therapeutic Areas
23.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
23.7. Capability and Expertise Expansions by CMOs to become One-Stop-Shops
23.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
23.9. Increase in Financial Inflow and Outsourcing Budgets
23.10. Challenges Faced by both Sponsors and Service Providers
23.10.1. Concerns Related to Single Use Systems
23.10.2. Issues Related to Capacity Fluctuations
23.11. Concluding Remarks

24. SURVEY ANALYSIS
24.1. Chapter Overview
24.1.1. Overview of Respondents
24.1.2. Analysis by Designation of Respondents
24.2. Analysis by Biologics Manufacturing Expertise
24.3. Analysis by Scale of Manufacturing
24.4. Analysis by Location of Production Facilities
24.5. Analysis by Type of Expression Systems Used
24.6. Analysis by Type of Bioreactors
24.7. Analysis by Mode of Operation of Bioreactors

25. INTERVIEW TRANSCRIPTS
25.1. Chapter Overview
25.2. Andrea Conforto, Sales & Marketing – Bioservices Director, Olon
25.3. Astrid Brammer, Senior Manager Business Development, Richter-Helm
25.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie (Q2 2015)
25.5. Christian Bailly, Director of CDMO, Pierre Fabre
25.6. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
25.7. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
25.8. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
25.9. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
25.10. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
25.11. Kevin Daley, Director Pharmaceuticals, Novasep
25.12. Mark Wright, ex-Site Head, Grangemouth, Piramal Healthcare
25.13. Max Rossetto, General Manager – Business Development, Luina Bio
25.14. Nicolas Grandchamp, R&D Leader, GEG Tech
25.15. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
25.16. Sebastian Schuck, Head of Business Development, Wacker Biotech
25.17. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
25.18. Marco Schmeer, Ex-Project Manager And Tatjana Buchholz, Marketing Manager, Plasmid Factory
25.19. Tim Oldham (ex-Chief Executive Officer, Cell Therapies

26. APPENDIX 1: TABULATED DATA
 
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Types of Biopharmaceuticals
Figure 3.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 3.3 Stages of the Biomanufacturing Process
Figure 3.4 Types of Third-Party Service Providers
Figure 3.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 4.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical CMOs: Distribution by Company Size
Figure 4.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-
Figure 4.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical CMOs: Distribution by Company Size, Year of Establishment and Location of Headquarters
Figure 4.6 Biopharmaceutical CMOs: Distribution by Type of Product
Figure 4.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
Figure 4.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and
Figure 4.9 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
Figure 4.10 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.11 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
Figure 4.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
Figure 4.13 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
Figure 4.14 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Figure 4.15 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactors
Figure 5.1 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Figure 5.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
Figure 5.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 5.4 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
Figure 5.5 Biopharmaceutical Contract Manufacturing Facilities: North America
Figure 5.6 Biopharmaceutical Contract Manufacturing Facilities: Europe
Figure 5.7 Biopharmaceutical Contract Manufacturing Facilities: Asia-Pacific
Figure 6.1 Biopharmaceutical Industry: The US Market Scenario
Figure 6.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 6.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 6.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 6.5 AGC: Annual Revenues (JPY Billion)
Figure 6.6 Catalent: Service Portfolio
Figure 6.7 Catalent: Biosimilars Service Portfolio
Figure 6.8 Catalent: Annual Revenues (USD Million)
Figure 6.9 Cytiva: Service Portfolio
Figure 6.10 Cytiva: Annual Revenues (USD Million)
Figure 6.11 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.12 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
Figure 6.13 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Figure 6.14 KBI Biopharma: Service Portfolio
Figure 6.15 Patheon: Service Portfolio
Figure 6.16 Patheon: Services and Solutions for Biologics
Figure 6.17 Patheon: Annual Revenues (USD Million)
Figure 6.18 Piramal Enterprises: Annual Revenues (INR Billion)
Figure 7.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 7.2 EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
Figure 7.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Figure 7.4 Boehringer Ingelheim: Annual Revenues (EUR Billion)
Figure 7.5 Lonza: Service Portfolio
Figure 7.6 Lonza: Annual Revenues (CHF Billion)
Figure 7.7 Lonza: Revenues by Business Divisions (CHF Billion)
Figure 7.8 Novasep: Products Portfolio
Figure 7.9 Novasep: Annual Revenues (EUR Million)
Figure 7.10 Rentschler Biopharma: Service Portfolio
Figure 7.11 Sandoz: Annual Revenues (USD Billion)
Figure 8.1 Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
Figure 8.2 Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
Figure 8.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 8.4 Biopharmaceutical Contract Manufacturing in China: Challenges
Figure 8.5 WuXi Biologics: Service Portfolio
Figure 8.6 Wuxi Biologics: Annual Revenues (RMB Million)
Figure 8.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 8.8 Biopharmaceutical Contract Manufacturing in India: Challenges
Figure 8.8 Minaris Regenerative Medicine: Service Portfolio
Figure 8.9 Takara Bio: Service Portfolio
Figure 8.10 Takara Bio: Annual Revenues (CNY Billion)
Figure 8.11 Celltrion: Service Portfolio
Figure 8.12 Celltrion: Annual Revenues (KRW Billion)
Figure 8.13 Samsung BioLogics: Service Portfolio
Figure 8.14 Samsung BioLogics: Annual Revenues from CMO Operations (KRW Billion)
Figure 8.15 Cell Therapies: Service Portfolio
Figure 8.16 Luina Bio: Service Portfolio
Figure 9.1 Structure of a Bispecific Antibody
Figure 9.2 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Figure 9.3 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Figure 9.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 9.5 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 9.6 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
Figure 9.7 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
Figure 9.8 Decentralized Manufacturing: Process Model
Figure 9.9 Cell Therapy Manufacturing: Challenges and Growth Drivers
Figure 9.10 Cell Therapy: Potency as Critical Quality Attribute
Figure 9.11 Stem Cell Therapies: Distribution by Phase of Development
Figure 9.12 T-Cell Therapies: Distribution by Phase of Development
Figure 9.13 Gene Therapies: Distribution by Stage of Development
Figure 9.14 Gene Therapies: Distribution by Phase of Development
Figure 9.15 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
Figure 9.16 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
Figure 9.17 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
Figure 9.18 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
Figure 9.19 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 9.20 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 10.1 Manufacturing Stages of a Biosimilar Product
Figure 10.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 10.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 10.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 10.5 Pipeline Analysis of Biosimilars, 2013 versus 2020
Figure 10.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 11.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Figure 11.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 12.1 Benefits Associated with In-House Manufacturing
Figure 12.2 Risks Associated with In-House Manufacturing
Figure 12.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 12.4 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
Figure 12.5 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
Figure 13.1 Make versus Buy Decision Making Framework
Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
Figure 14.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 14.3 Big Pharma Players: Distribution by Purpose of Initiative
Figure 14.4 Big Pharma Players: Distribution by Type of Initiative
Figure 14.5 Big Pharma Players: Distribution by Type of Partnership
Figure 14.6 Big Pharma Players: Distribution by Type of Expansion
Figure 14.7 Big Pharma Players: Distribution by Scale of Operation
Figure 14.8 Big Pharma Players: Distribution by Types of Biologics Manufactured
Figure 14.9 Big Pharma Players: Distribution by Year of Initiative and Company
Figure 14.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 14.11 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 14.12 Big Pharma Players: Distribution by Region of Expansion and Company
Figure 14.13 Big Pharma Players: Distribution by Types of Biologics Manufactured and Company
Figure 14.14 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 15.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
Figure 15.3 Partnerships and Collaborations: Distribution by Focus Area
Figure 15.4 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model Adopted
Figure 15.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
Figure 15.6 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
Figure 15.7 Partnerships and Collaborations: Distribution by Year and Types of Biologics Manufactured
Figure 15.8 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model
Figure 15.9 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Geography
Figure 15.10 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.11 Most Active Players: Distribution by Number of Partnerships
Figure 15.12 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 15.13 Partnerships and Collaborations: Distribution by Geographical Location (Local and International)
Figure 16.1 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
Figure 16.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 16.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 16.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 16.5 Mergers and Acquisitions: Distribution by Intercontinental and Intracontinental Deals
Figure 16.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 16.7 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 16.8 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Figure 16.9 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
Figure 16.10 Heat Map Analysis: Distribution by Types of Biologics Manufactured and Key Value Drivers
Figure 16.11 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 17.1 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
Figure 17.2 Facility Expansions: Distribution by Purpose of Expansion
Figure 17.3 Facility Expansions: Distribution by Year and Purpose of Expansion
Figure 17.4 Facility Expansions: Distribution by Types of Biologics Manufactured
Figure 17.5 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
Figure 17.6 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 17.7 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 17.8 Facility Expansions: Most Active Players
Figure 17.9 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 17.10 Facility Expansions: Regional Comparison 2016-2018 and 2016-2020 Scenario
Figure 19.1 Biopharma CMOs Global Capacity: Distribution by Range of Installed Capacity
Figure 19.2 Capacity Analysis: Distribution by Company Size
Figure 19.3 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
Figure 19.4 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
Figure 19.5 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Figure 19.6 Capacity Analysis: Contract Biomanufacturing Capacity in the US
Figure 19.7 Capacity Analysis: Contract Biomanufacturing Capacity in Canada
Figure 19.8 Capacity Analysis: Contract Biomanufacturing Capacity in the UK
Figure 19.9 Capacity Analysis: Contract Biomanufacturing Capacity in Germany
Figure 19.10 Capacity Analysis: Contract Biomanufacturing Capacity in France
Figure 19.11 Capacity Analysis: Contract Biomanufacturing Capacity in Italy
Figure 19.12 Capacity Analysis: Contract Biomanufacturing Capacity in Spain
Figure 19.13 Capacity Analysis: Contract Biomanufacturing Capacity in Rest of Europe
Figure 19.14 Capacity Analysis: Contract Biomanufacturing Capacity in China
Figure 19.15 Capacity Analysis: Regional Contract Biomanufacturing Capacity in South Korea
Figure 19.16 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Taiwan
Figure 19.17 Capacity Analysis: Regional Contract Biomanufacturing Capacity in India
Figure 19.18 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Japan
Figure 19.19 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Rest of Asia-Pacific
Figure 20.1 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
Figure 20.2 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Figure 20.3 Biologics: Demand and Supply Scenario, 2020-2030 (Million Liters)
Figure 20.4 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
Figure 20.5 ADC Therapeutics: Demand and Supply Scenario, 2020-2030
Figure 20.6 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
Figure 20.7 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
Figure 21.1 Biopharmaceutical Contract Manufacturing: Market Forecast Framework
Figure 21.2 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 21.3 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030 (USD Billion)
Figure 21.4 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030 (USD Billion)
Figure 21.5 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030 (USD Billion)
Figure 21.6 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
Figure 21.7 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 21.8 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 21.9 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
Figure 21.10 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 21.11 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 21.12 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
Figure 21.13 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
Figure 21.14 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.15 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.16 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.17 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.18 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.19 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.20 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.21 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.22 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.23 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.24 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.25 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 21.26 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
Figure 21.27 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
Figure 21.28 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030 (USD Billion)
Figure 21.29 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
Figure 21.30 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
Figure 21.31 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 21.32 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.33 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.34 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.35 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.36 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.37 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.38 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.39 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.40 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.41 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.42 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.43 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 21.44 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030 (USD Billion)
Figure 21.45 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030 (USD Billion)
Figure 21.46 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030 (USD Billion)
Figure 21.47 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
Figure 21.48 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
Figure 21.49 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.50 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.51 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.52 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.53 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.54 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.55 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.56 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.57 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.58 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.59 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.60 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030 (USD Billion)
Figure 21.61 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 22.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 22.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2002-2020
Figure 22.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Survey Analysis: Distribution of Respondents by Company Type
Figure 24.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 24.3 Survey Analysis: Distribution of Respondents by Designation
Figure 24.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 24.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 24.6 Survey Analysis: Distribution by Location of Production Facilities
Figure 24.7 Survey Analysis: Distribution by Types of Expression Systems Used
Figure 24.8 Survey Analysis: Distribution by Types of Bioreactors
Figure 24.9 Survey Analysis: Distribution by Mode of Operation of Bioreactors

List Of Tables
Table 3.1 Mammalian versus Microbial Expression Systems
Table 4.1 List of Biopharmaceutical CMOs
Table 4.2 Biopharmaceutical CMOs: Information on Type of Product
Table 4.3 Biopharmaceutical CMOs: Information on Types of Biologics Manufactured
Table 4.4 Biopharmaceutical CMOs: Information on Scale of Operation,
Table 4.5 Biopharmaceutical CMOs: Information on Types of Expression Systems Used,
Table 4.6 Biopharmaceutical CMOs: Information on Types of Bioreactors,
Table 4.7 Biopharmaceutical CMOs: Information on Mode of Operation of Bioreactors,
Table 5.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 5.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 5.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Biologics Manufacturing Facilities
Table 6.3 AGC Biologics: Partnerships
Table 6.4 AGC Biologics: Recent Expansions
Table 6.6 Catalent: Company Overview
Table 6.7 Catalent: Biologics Manufacturing Facilities
Table 6.8 Catalent: Partnerships
Table 6.9 Catalent: Recent Expansions
Table 6.11 Cytiva: Company Overview
Table 6.12 Cytiva: Manufacturing Facilities
Table 6.13 Cytiva: Partnerships
Table 6.14 Cytiva: Recent Expansions
Table 6.16 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.17 FUJIFILM Diosynth Biotechnologies: Biopharmaceutical Facilities
Table 6.18 FUJIFILM Diosynth Biotechnologies: Partnerships
Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Expansions
Table 6.21 KBI Biopharma: Company Overview
Table 6.22 KBI Biopharma: Overview of Manufacturing Capabilities
Table 6.23 KBI Biopharma: List of Partnerships
Table 6.25 Patheon: Company Overview
Table 6.26 Patheon: Biopharmaceutical Manufacturing and Development Facilities
Table 6.27 Patheon: Partnerships
Table 6.28 Patheon: Recent Expansions
Table 6.30 Piramal Pharma Solutions: Company Overview
Table 6.31 Piramal Pharma Solutions: Facilities
Table 7.1 FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
Table 7.2 Boehringer Ingelheim: Company Overview
Table 7.3 Boehringer Ingelheim: Biopharmaceutical Facilities
Table 7.4 Boehringer Ingelheim: Partnerships
Table 7.5 Boehringer Ingelheim: Recent Expansions
Table 7.7 Lonza: Company Overview
Table 7.8 Lonza: Biopharmaceutical Facilities
Table 7.9 Lonza: Partnerships
Table 7.10 Lonza: Recent Expansions
Table 7.12 Novasep: Company Overview
Table 7.13 Novasep: Biologics Manufacturing Facilities
Table 7.14 Novasep: Partnerships
Table 7.15 Novasep: Recent Expansions
Table 7.17 Olon: Company Overview
Table 7.18 Olon: Biopharmaceutical Facilities
Table 7.20 Rentschler Biopharma: Company Overview
Table 7.21 Rentschler Biopharma: Partnerships
Table 7.22 Rentschler Biopharma: Recent Expansions
Table 7.24 Sandoz: Company Overview
Table 8.1 WuXi AppTec (WuXi Biologics): Company Overview
Table 8.2 WuXi Biologics: Partnerships
Table 8.3 WuXi Biologics: Recent Expansions
Table 8.4 WuXi Biologics: Future Outlook
Table 8.5 Kemwell Biopharma: Company Overview
Table 8.6 Kemwell Biopharma: Partnerships
Table 8.7 Kemwell Biopharma: Recent Expansions
Table 8.8 Minaris Regenerative Medicine: Company Overview
Table 8.9 Minaris Regenerative Medicine: Manufacturing Facilities
Table 8.10 Minaris Regenerative Medicine: Partnerships
Table 8.11 Minaris Regenerative Medicine: Future Outlook
Table 8.12 Takara Bio: Company Overview
Table 8.13 Takara Bio: Biologics Manufacturing Facilities
Table 8.14 Takara Bio: Future Outlook
Table 8.15 Celltrion: Company Overview
Table 8.16 Celltrion: Biologics Manufacturing Facilities
Table 8.17 Celltrion: Future Outlook
Table 8.18 Samsung BioLogics: Company Overview
Table 8.19 Samsung BioLogics: Biopharmaceutical Facilities
Table 8.20 Samsung BioLogics: Partnerships
Table 8.21 Samsung BioLogics: Recent Expansions
Table 8.22 Samsung BioLogics: Future Outlook
Table 8.23 Cell Therapies: Company Overview
Table 8.24 Cell Therapies: Partnerships
Table 8.25 Cell Therapies: Future Outlook
Table 8.26 Luina Bio: Company Overview
Table 8.27 Luina Bio: Partnerships
Table 8.28 LuinaBio: Recent Expansions
Table 8.29 Luina Bio: Future Outlook
Table 9.1 Bispecific Antibody Therapeutics: Information on Developer(s), Platform / Technology Used, Phase of Development, Target Antigen and Antibody Format,
Table 9.2 Bispecific Antibody Therapeutics: Information on Developer(s), Technology used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 9.3 List of Other Emerging Multivalent Drug Candidates
Table 9.4 Bispecific Antibody Therapeutics: List of Technology Platforms,
Table 9.5 List of Bispecific Antibody CMOs: Information on Company Specifications
Table 9.6 Commonly Used Cytotoxins for ADC Therapeutics
Table 9.7 Occupational Exposure Limit Bands, Safebridge Consultants
Table 9.8 ADC Therapeutics: Approved / Clinical Pipeline
Table 9.8 Novel Drug Conjugates
Table 9.10 ADC Contract Manufacturing Service Providers: List of Companies
Table 9.11 Application of Cell-based Therapies
Table 9.12 Cell-based Therapies: Commercialized Products,
Table 9.13 Assessments for Key Cell Therapy Manufacturing Steps
Table 9.14 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 9.15 Cell Therapy Contract Manufacturers: Type of Cell Therapy
Table 9.16 List of Cell Therapy Contract Manufacturers
Table 9.17 Viral Vectors Manufacturers: Information on Type of Viral Vector Used
Table 9.18 Viral Vectors: List of Manufacturers
Table 9.19 Plasmid DNA: List of Manufacturers
Table 10.1 Biosimilars Pipeline Analysis: Distribution by Drug Class, 2013 and 2020
Table 10.2 Biosimilar Pipeline Analysis: Distribution by Reference Products, 2013 and 2020
Table 10.3 List of Biosimilars Contract Manufacturing Service Providers
Table 11.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 11.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 11.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 12.1 List of FDA Approved Biologics (2016-2020)
Table 14.1 Big Pharma Players: List of Biopharmaceutical Manufacturing Initiatives
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Collaborations, 2015 – 2020
Table 15.2 Biopharmaceutical Contract Manufacturing Partnerships and Collaborations: Information on Types of Biologics Manufactured,
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015 - 2020
Table 16.2 Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologics, 2015- 2020
Table 16.3 Mergers and Acquisitions: Deal Multiples, 2015- 2020
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Expansions
Table 18.1 Biopharmaceutical CMOs: Funding Instances
Table 19.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
Table 19.2 Capacity Analysis: Average Capacity per Category
Table 19.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems
Table 19.4 Capacity Analysis: Average Capacity for Microbial Expression Systems
Table 19.5 Capacity Analysis: Global Contract Biomanufacturing Capacity
Table 20.1 Annual Biomanufacturing Capacity, 2019-2024 (Million Liters)
Table 20.2 ADC Therapeutics: Annual Demand for Outsourcing, 2020-2030 (in kg)
Table 20.3 ADC Therapeutics: Annual Supply for Outsourcing, 2018-2030 (in Kilograms)
Table 22.1 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best-selling Biologics
Table 24.1 Survey Analysis: Overview of Respondents
Table 24.2 Survey Analysis: Distribution of Respondents by Designation
Table 24.3 Survey Analysis: Biologics Manufacturing Expertise
Table 24.4 Survey Analysis: Scale of Manufacturing
Table 24.5 Survey Analysis: Location of Production Facilities
Table 24.6 Survey Analysis: Types of Expression Systems Used
Table 24.7 Survey Analysis: Types of Bioreactors
Table 24.8 Survey Analysis: Mode of Operation of Bioreactors
Table 26.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Table 26.2 Biopharmaceutical CMOs: Distribution by Company Size
Table 26.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-wise)
Table 26.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
Table 26.5 Biopharmaceutical CMOs: Distribution by Type of Product
Table 26.6 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
Table 26.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Location of Headquarters
Table 26.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
Table 26.9 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 26.10 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
Table 26.11 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
Table 26.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
Table 26.13 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Table 26.14 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactor
Table 26.15 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Table 26.16 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
Table 26.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 26.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
Table 26.19 AGC Biologics: Annual Revenues (JPY Billion)
Table 26.20 Catalent: Annual Revenues (USD Million)
Table 26.21 Cytiva: Annual Revenues (USD Million)
Table 26.22 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
Table 26.23 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Table 26.24 Patheon: Annual Revenues (USD Million)
Table 26.25 Piramal Enterprises: Annual Revenues (INR Billion)
Table 26.26 Boehringer Ingelheim: Annual Revenues (EUR Billion)
Table 26.27 Lonza: Annual Revenues (CHF Billion)
Table 26.28 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 26.29 Novasep: Annual Revenues (EUR Million)
Table 26.30 Sandoz: Annual Revenues (USD Million)
Table 26.31 Wuxi Biologics: Annual Revenues (RMB Million)
Table 26.32 Celltrion: Annual Revenues (KRW Billion)
Table 26.33 Samsung Biologics: Annual Revenues from CMO Operations (KRW Billion)
Table 26.34 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Table 26.35 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Table 26.36 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 26.37 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
Table 26.38 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
Table 26.39 Stem Cell Therapies: Distribution by Phase of Development
Table 26.40 T-Cell Therapies: Distribution by Phase of Development
Table 26.41 Gene Therapies Pipeline: Distribution by Stage of Development
Table 26.42 Gene Therapies Pipeline: Distribution by Phase of Development
Table 26.43 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
Table 26.44 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
Table 26.45 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
Table 26.46 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
Table 26.47 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 26.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 26.49 Pipeline Analysis of Biosimilars, 2013 versus 2020
Table 26.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Table 26.51 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
Table 26.52 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
Table 26.53 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
Table 26.54 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 26.55 Big Pharma Players: Distribution by Purpose of Initiative
Table 26.56 Big Pharma Players: Distribution by Type of Initiative
Table 26.57 Big Pharma Players: Distribution by Type of Partnership
Table 26.58 Big Pharma Players: Distribution by Type of Expansion
Table 26.59 Big Pharma Players: Distribution by Scale of Operation
Table 26.60 Big Pharma Players: Distribution by Types of Biologics Manufactured
Table 26.61 Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 26.62 Big Pharma Players: Distribution by Year and Type of Initiative
Table 26.63 Big Pharma Players: Distribution by Region of Expansion and Company
Table 26.64 Partnerships and Collaborations: Distribution by Year of Partnership
Table 26.65 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
Table 26.66 Partnerships and Collaborations: Distribution by Focus Area
Table 26.67 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model
Table 26.68 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
Table 26.69 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
Table 26.70 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Biologics Manufactured
Table 26.71 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model Adopted
Table 26.72 Partnerships and Collaborations: Distribution of Manufacturing Agreements by Types of Biologics Manufactured and Geography
Table 26.73 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 26.74 Partnerships and Collaborations: Most Active Players
Table 26.75 Partnerships and Collaborations: Distribution by Most Active Players and Type of Partnership
Table 26.76 Partnerships and Collaborations: Distribution by Geographical Location (Local and International Agreements)
Table 26.77 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
Table 26.78 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 26.79 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 26.80 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 26.81 Most Active Acquirers: Distribution by Number of Acquisitions
Table 26.82 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 26.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Table 26.84 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
Table 26.85 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 26.86 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 26.87 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
Table 26.88 Facility Expansions: Distribution by Purpose of Expansion
Table 26.89 Facility Expansions: Distribution by Year of Expansion and Purpose of Expansion
Table 26.90 Facility Expansions: Distribution by Types of Biologics Manufactured
Table 26.91 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
Table 26.92 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.93 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.94 Facility Expansions: Most Active Players
Table 26.95 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 26.96 Capacity Analysis: Distribution by Company Size
Table 26.97 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
Table 26.98 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
Table 26.99 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Table 26.100 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
Table 26.101 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Table 26.102 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
Table 26.103 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
Table 26.104 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
Table 26.105 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.106 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.107 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.108 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.109 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
Table 26.110 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 26.111 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size USD Billion)
Table 26.112 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
Table 26.113 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Table 26.114 Biopharmaceutical Contract Manufacturing Market in North America: 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.115 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.116 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.117 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.118 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.119 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.120 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.121 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.122 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.123 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.124 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.125 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.126 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.127 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.128 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.129 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.130 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.131 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.132 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.133 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.134 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.135 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.136 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.137 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.138 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.139 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.140 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.141 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.142 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.143 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.144 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.145 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.146 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: 2020-2030, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.147 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.148 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.149 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.150 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.151 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.152 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.153 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.154 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.155 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.156 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.157 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.158 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.159 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.160 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.161 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.162 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.163 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.164 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.165 Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002-2020
Table 26.166 Survey Analysis: Distribution of Respondents by Company Type
Table 26.167 Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 26.168 Survey Analysis: Distribution of Respondents by Designation
Table 26.169 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 26.170 Survey Analysis: Distribution by Scale of Manufacturing
Table 26.171 Survey Analysis: Distribution by Location of Production Facilities
Table 26.172 Survey Analysis: Distribution by Types of Expression Systems Used
Table 26.173 Survey Analysis: Distribution by Types of Bioreactors
Table 26.174 Survey Analysis: Distribution by Mode of Operation of Bioreactors

Note: Product cover images may vary from those shown
  • 3P Biopharmaceuticals
  • 3SBio
  • 53 Biologics
  • A.R. BROWN
  • Aalto Scientific
  • Labyrinth BioPharma (Formely known as AB BioTechnologies)
  • AbbVie Contract Manufacturing
  • AbCellera Biologics
  • Abeona Therapeutics
  • ABL
  • ABL Bio
  • Abzena
  • Acasti Pharma 
  • Accellta
  • ACES Pharma
  • Achilles Therapeutics 
  • Acticor Biotech 
  • Adagene
  • Adaptimmune
  • AdaptVac 
  • ADC Bio
  • Adimmune
  • Advanced Biotherapeutics Consulting
  • Advanced Cell Technology 
  • Advanced Scientifics (Acquired by Thermo Fisher Scientific)
  • Advanced Therapy Treatment Centre (ATTC)
  • Advaxis
  • Advent Bioservices 
  • Aeras 
  • Affibody
  • Affinita Biotech
  • Affinity Life Sciences
  • Affymetrix
  • Afton Scientific
  • AGC Biologics
  • Agilis Biotherapeutics
  • Agilux Laboratories
  • Airway Therapeutics
  • Ajinomoto Althea
  • Ajinomoto Bio-Pharma Services
  • Ajinomoto OmniChem
  • Akorn
  • Akouos 
  • Akron Biotech
  • Akshaya Bio
  • Alcami
  • Aldevron
  • Alexion
  • Allele Biotechnology & Pharmaceuticals
  • Allevi 
  • Alliance Protein Laboratories APL (Acquired by KBI Biopharma)
  • Alligator Bioscience
  • Almac Group
  • Altor BioScience
  • Amaran Biotechnology
  • Amatsigroup (Acquired by Eurofins)
  • AmbioPharm
  • American Peptide Company (Acquired by Bachem)
  • Amgen
  • Andes Biotechnologies
  • Antabio
  • Anthos Therapeutics
  • apceth Biopharma
  • Aptevo Therapeutics
  • Aravive 
  • Arch Biopartners
  • Arcturus Therapeutics
  • Arcus Biosciences
  • Arecor 
  • argenx
  • Ash Stevens
  • ASLAN Pharmaceuticals
  • Asterias Biotherapeutics
  • AstraZeneca
  • Asymchem
  • Asymptote (Acquired by GE Healthcare)
  • Athersys
  • Austrianova
  • AutekBio
  • Autolus
  • Avecia (acquired by Nitto Denko)
  • Avid Bioservices
  • Avrio Biopharmaceuticals
  • Axcellerate Pharma
  • Axovant Sciences
  • Babraham Bioscience Technologies
  • Baccinex 
  • Bachem
  • Batavia Biosciences
  • Battelle
  • Baxter BioPharma Solutions
  • Baylor College of Medicine
  • Baylor Institute for Immunology Research 
  • Baylor Scott & White Research Institute (BSWRI)
  • BCN Peptides 
  • BDI biotech
  • Beam Therapeutics 
  • BeiGene
  • Beijing Kawin Bio-Tech
  • Berkeley Lights
  • Bexion Pharmaceuticals 
  • Bioindustry Association (BIA) BIA Separations
  • BIBITEC
  • Bill & Melinda Gates Foundation
  • BINEX
  • Bio Elpida
  • Bioasis
  • BioCell 
  • BioConnection
  • Bio-Ess Laboratories
  • Biofabri
  • Bio Farma
  • Bioinova 
  • BioInvent
  • Biological E.
  • BioMARC
  • Biomay
  • BioMeca
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Biomeva (Acquired by AGC Biologics)
  • BiondVax Pharmaceuticals
  • Bionova Scientific
  • BioNTech
  • Biopolis Lifesciences
  • BiosanaPharma
  • BioSig Technologies
  • Biospring Partners
  • Bio-Synergy 
  • Bio-Synthesis
  • BioTechnique
  • Biotechpharma 
  • BioVectra
  • Bioverativ
  • Biovian
  • Bioworkshops
  • BioXcellence
  • Bliss Biopharmaceutical
  • Blue Stream Laboratories
  • bluebird bio
  • Boehringer Ingelheim
  • Boston Children’s Hospital
  • BPL Biologics
  • Brammer Bio
  • Bristol Myers Squibb
  • Bryllan
  • BSP Pharmaceuticals
  • Burrard Pharmaceuticals
  • C3i Solutions
  • Plasma Industries Belgium (Formely known as CAF-DCF)
  • Caisson Biotech
  • Calviri
  • Calypso Biotech
  • Cambridge Pharmaceuticals
  • CANbridge
  • Cancer Research Technology
  • Canton Biologics
  • Capsugel
  • Capua BioServices
  • CARBOGEN AMCIS
  • Catalent Biologics
  • Catalyst Biosciences
  • CDR-Life
  • Cell and Gene Therapy Catapult
  • Cell Culture Company
  • Cell Medica
  • Cell Therapies 
  • Celladon 
  • Cellectis
  • CEllforCure 
  • CellGenix
  • Cellin Technologies
  • Celltrion
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Celonic
  • Celsis (Acquired by Charles River Laboratories)
  • Cenexi
  • Centaur Biopharmaceutical
  • Center for Molecular Medicine Cologne (CMMC)
  • Centers for Disease Control and Prevention (CDC)
  • Centre for Process Innovation (CPI)
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Commercial & External Partnership, Industrial Affairs (CEPiA)
  • Cerbios-Pharma
  • Cerium Pharmaceuticals
  • CEVEC Pharmaceuticals 
  • Charles River
  • ChemPartner
  • Chime Biologics
  • China Regenerative Medicine International (CRMI)
  • Chinese Peptide 
  • Chiome Bioscience
  • CiMaas
  • CiRA Foundation 
  • Citryll
  • California Milk Advisory Board (CMAB)
  • CMC Biologics
  • CMIC
  • Cobra Biologics (Acquired by Cognate BioServices)
  • Cochin Shipyard (CSL)
  • Cognate BioServices
  • Coherus BioSciences
  • Coldstream Laboratories
  • Columbia University
  • CombiGene
  • Contract Manufacturing and Development 
  • Cook MyoSite
  • CordenPharma
  • Coretherapix (Acquired by TiGenix)
  • CPC Scientific
  • CRC for Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)
  • Creative Biolabs
  • CRISPR Therapeutics
  • Cryoport
  • CSBio
  • CureCell
  • Cynata Therapeutics
  • Cytiva
  • CytoDyn
  • CytoSen Therapeutics (Acquired by Kiadis)
  • Cytovance Biologics (Acquired by Hepalink USA)
  • CyTuVax
  • Daiichi Sankyo
  • Dalton Partners
  • Dalton Pharma Services (Acquired by Seikagaku)
  • DanDrit Biotech
  • DaTaMabs
  • DCPrime
  • Denali Therapeutics 
  • Dendreon
  • US Department of Defense
  • DiNAQOR 
  • Disposable-Lab (Acquired by Amatsi)
  • DM Bio
  • Drugs for Neglected Diseases Initiative (DNDi)Downing
  • Dyadic International
  • Dyax (Acquired by Shire)
  • Educell
  • EirGenix
  • Eisai
  • Elion Labs (Acquired by KBI)
  • Emergent BioSolutions
  • Emerson
  • European Regional Development Fund (EDRF)
  • Enleofen Bio 
  • Enzene
  • Epitopoietic Research (ERC)
  • Esco Aster
  • Etinpro (Beijing)
  • EuBiologics
  • Eucodis Bioscience
  • EUFETS
  • Eurofins Scientific
  • Eurogentec 
  • Euticals
  • EVER Pharma
  • ExCellThera
  • Exelead
  • Exelixis 
  • FairJourney Biologics
  • Faron Pharmaceuticals
  • Federal Ministry of Education and Research (BMBF)
  • FinVector
  • FloDesign Sonics
  • Florida Biologix
  • For‐Robin
  • Forty Seven
  • Forum for Innovative Regenerative Medicine (FIRM) 
  • Fred Hutchinson Cancer Research Center
  • Frederick National Laboratory 
  • Freeline
  • FUJIFILM Diosynth Biotechnologies
  • Fusion Antibodies
  • Gadea Pharmaceutical (Acquired by AMRI) 
  • Gallant Custom Laboratories 
  • GC Cell (Previously known as Green Cross Cell)
  • GE Healthcare
  • GeneCure Biotechnologies
  • GeneDesign
  • Genentech
  • Geneos Therapeutics
  • GeneScience Pharmaceuticals (Acquired by Changchun Hi-Tech Technology)
  • Gene-to-Proteins (GTP) Technology
  • GenIbet
  • Genome 
  • Genopis
  • Genprex
  • German Center for Infection Research (DZIF)
  • GigaGen
  • Gilead Sciences
  • GlycoSeLect 
  • Glycotope
  • Goodwin Biotechnology
  • Government of Canada
  • Government of Europe
  • Department for Business Energy and Industrial Strategy (BEIS)
  • GP Pharm
  • Grand River Aseptic Manufacturing (Acquired by Arlington Capital Partners)
  • Green Cross LabCell
  • GreenPak Biotech
  • Greffex
  • Grenoble Alpes University Hospital Griffith University
  • GlaxoSmithKline (GSK)
  • GTP Technology
  • Gubra
  • HIG Capital
  • HALIX
  • Hansa Biopharma 
  • Harbin Hou pu Tong tang Biotechnology 
  • Harbour BioMed
  • Harpoon Therapeutics
  • Heidelberg Pharma
  • Hemogenyx Pharmaceuticals
  • Hepalink USA
  • Histocell (Acquired by Noray)
  • Minaris Regenerative Medicine (Previously known as Hitachi Chemical Advanced          Therapeutics Solutions (HCATS)
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • Horizon Therapeutics
  • Hospira (Acquired by Pfizer)
  • Houston Methodist
  • Humanigen
  • Hummingbird Bioscience
  • Hybio Pharmaceutical
  • Hycult Biotech
  • Hygeia Health
  • International AIDS Vaccine Initiative (IAVI) 
  • IBC Generium
  • IBI Lorenzini
  • Icagen
  • Ichnos Sciences
  • ID Pharma
  • IDT Biologika
  • I-Mab
  • Immune Pharmaceuticals
  • ImmunoCellular Therapeutics
  • Immunocore
  • ImmunoGenesis
  • ImmunoTek Bio Centers 
  • Imperial Innovations
  • In3Bio
  • IncoCell Tianjin (A subsidiary of Boyalife)
  • Indapta Therapeutics
  • Industrial Strategy Challenge Fund (ISCF)
  • Inhibrx
  • Inno Biologics
  • Innovate UK
  • Innovation Network Corporation of Japan (INCJ)
  • Inovio Pharmaceuticals
  • Israel Institute for Biological Research (IIBR)
  • Institute for Research
  • INSERM-ANRS
  • Integrated DNA Technologies (IDT)
  • Integrity Biosolution (Acquired by Symyx Technologies)
  • IntellectiveBio
  • International Consortium of Investigative Journalists (ICIJ)
  • International Finance Corporation (IFC)
  • Intervacc
  • Invetech
  • Iovance Biotherapeutics
  • IQVIA
  • Irvine Scientific 
  • IsoPlexis
  • Istituto Biochimico Italiano Giovanni Lorenzini
  • IVERIC bio
  • Janssen Pharmaceuticals
  • Japan Tissue Engineering
  • Japanese Society for Regenerative Medicine
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Jianyi Biotechnology 
  • Jitsubo (Acquired by Sosei)
  • Johns Hopkins University School of Medicine
  • Johnson & Johnson
  • JOINN Biologics
  • JSR 
  • Jubilant HollisterStier
  • Juniper Pharmaceuticals
  • Juno Therapeutics
  • Junshi Biosciences
  • Just - Evotec Biologics
  • KABS Pharmaceutical Services 
  • Kamat Pharmatech
  • Kanaph Therapeutics
  • Kanda BioTech
  • Kaneka Eurogentec
  • KBI Biopharma
  • Kemwell BioPharma
  • Kiadis Pharma
  • Kite Pharma
  • Kodiak Sciences
  • KriSan Biotech
  • KUBio
  • LamKap Bio
  • LAMPIRE Biological Laboratories
  • Lava Therapeutics
  • Leanbio
  • LEUKOCARE
  • Levena Biopharma
  • LFB Biomanufacturing
  • LNC Therapeutics
  • Lonza
  • LSNE Contract Manufacturing
  • LucasPye BIO
  • Luina Bio (Previously known as PharmaSynth)
  • Lyophilization Technology
  • Lyophilization Services of New England (LSNE)
  • Lysogene
  • MabPlex
  • MAbSilico
  • Mab-Venture Biopharma
  • MacroGenics
  • Maine Biotechnology (Acquired by BBI )
  • Massachusetts Eye and Ear 
  • MassBiologics
  • MaSTherCell
  • Matica Biotechnology
  • Maven Capital Partners
  • Medeor Therapeutics
  • Medigene
  • MedImmune
  • MEDINET
  • Medisuns
  • Medix Biochemica
  • MEMO Therapeutics
  • Menarini Biotech
  • Merck
  • Merck Millipore
  • Meridian Life Science
  • Mesoblast
  • MicroBiopharm Japan
  • MicrofluidX
  • Mila’s Miracle Foundation
  • Milner Therapeutics Institute
  • Minneapolis Medical Research  Foundation (MMRF)
  • Mitsubishi Gas Chemical
  • Mitsubishi Tanabe Pharma
  • Moderna
  • Molecular Partners
  • MolMed (Acquired by AGC Biologics)
  • Morphotek
  • Merck Sharp & Dohme (MSD)
  • MTI-GlobalStem (Acquired by Thermo Fisher Scientific)
  • Multispan
  • Mycenax
  • Najít Technologies
  • Naobios
  • National Cancer Institute
  • National Center for Advancing Translational Sciences (NCATS)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Disease (NIAID)
  • Nature Technology
  • Navrogen
  • Neovacs
  • NeoVentures Biotechnology
  • Neuland Health Sciences 
  • NeuroFx
  • Neuway Pharma
  • Nikon CeLL innovation
  • Nitto Avecia Pharma Services
  • Nitto Denko Avecia
  • Northway BiotechPharma
  • Nouscom
  • Novartis
  • Novasep
  • Novavax
  • Novex Innovations
  • Numab Therapeutics
  • NYU Langone Health
  • OBI Pharma
  • Octane Biotech
  • Ocugen
  • Odylia
  • Ology Bioservices
  • Olon
  • Omeros
  • Omnia Biologics
  • OncoQuest
  • OncoVent
  • Ondek
  • Ono Pharmaceutical
  • Orchard
  • Orgenesis
  • ORPEGEN Peptide Chemicals 
  • Osaka University 
  • OSE Immunotherapeutics
  • OsoBio (Acquired by AMRI)
  • Otsuka Pharmaceutical
  • Oxford Biomedica
  • Oxford Genetics
  • Oxford MEStar 
  • PacificGMP (Acquired by Abzena)
  • PaizaBio
  • Pall Corporation
  • Panacea Biotec
  • PanCELLa
  • Panolos Bioscience
  • Paragon Bioservices
  • Parker Institute for Cancer Immunotherapy
  • Particle Sciences
  • PATH
  • Patheon (Acquired by Thermo Fisher Scientific)
  • PaxVax
  • PCI Pharma Services
  • PCT
  • Pfizer
  • Pfizer CentreOne
  • Phanes Therapeutics
  • Pharma Bio
  • PharmaCell
  • Pharmedartis
  • Pharmicell
  • PHion Therapeutics
  • Pierre Fabre
  • Pionyr Immunotherapeutics
  • Piramal Pharma Solutions
  • PlasmidFactory
  • Polaris Pharmaceuticals
  • Polpharma Biologics
  • Polymun Scientific
  • PolyPeptide 
  • Portola Pharmaceuticals
  • Porton Biopharma
  • Praxis Pharmaceutical
  • Precision Antibody
  • Precision NanoSystems
  • Prevail Therapeutics
  • Immutep (Formely Known as Prima BioMed) 
  • PrimaPharma
  • Vivoryon Therapeutics (Formely known as Probiodrug)
  • ProBioGen (Acquired by Minapharm Pharmaceuticals)
  • Profectus BioSciences
  • Prometic Life Sciences
  • Propanc Biopharma
  • Proteon Therapeutics
  • Provia Labs
  • PTC Therapeutics 
  • PX'Therapeutics
  • Q-Biologicals (Acquired by Amatsigroup)
  • Radimmune Therapeutics
  • Refana
  • REGENXBIO
  • Regulus Therapeutics
  • Relief Therapeutics
  • ReNeuron
  • Rentschler Biopharma
  • Rentschler Biotechnologie
  • Rentschler Fill solutions
  • RevaTis
  • Rexgenero
  • Richter-Helm BioLogics
  • Ridgeway Biologicals
  • River Vision Development
  • Roche
  • Rocket Pharmaceuticals 
  • Roslin Cell Therapies
  • Ruibo Bio-Technology
  • Saiba 
  • Sam Chun Dang Pharm
  • Samsung BioLogics
  • SanBio
  • Sandoz
  • Sanofi
  • Sanofi-Aventis
  • Sanpower 
  • Santen Pharmaceutical
  • Sarepta Therapeutics
  • Sartorius Stedim Biotech 
  • Scancell
  • Scientific Protein Laboratories (Acquired by Shenzhen Hepalink Pharmaceutical)
  • ScinoPharm
  • Selecta Biosciences
  • Seneca Partners
  • Senn Chemicals
  • Serendex Pharmaceuticals (Acquired by Savara Pharmaceuticals)
  • Serum Institute of India
  • Servier
  • Shanghai Jiao Tong University
  • Sheba Medical Center 
  • Shengnuo Peptide
  • Shenzhen JYMed Technology
  • Shenzhen Watsin Genetech 
  • Shire (acquired by Takeda)
  • Showa Denko 
  • Siam Bioscience 
  • Siegfried
  • SillaJen
  • Singota Solutions
  • SIRION Biotech
  • Sistemic
  • Sonnet BioTherapeutics 
  • Spicona
  • ST Pharm
  • Stanford University School of Medicine
  • STCube
  • Stelis BioSource
  • Stemmatters
  • Stratophase
  • Sumagen
  • Sumitomo Dainippon Pharma
  • Sun Pharma
  • Surface Oncology 
  • Surrozen
  • Symbiosis Pharmaceutical Services
  • Symphogen
  • Wacker Biotech (Formely known as Wacker)
  • Synklino
  • Synpromics
  • Synthace
  • Synthelis
  • Takara Bio
  • Taron Solutions
  • TCR2 Therapeutics
  • Tectron 
  • Telix Pharmaceuticals
  • Terumo BCT
  • The Chemistry Research Solution (TCRS)
  • Development Bank of Wales
  • John Hopkins University
  • The Michael J. Fox Foundation
  • The Native Antigen Company
  • Theracell Advanced Biotechnology
  • Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)
  • University of Manchester
  • Therapure Biopharma (Acquired by Resilience Biotechnologies)
  • Theravectys
  • Thermo Fisher Scientific
  • Thousand Oaks Biopharmaceuticals
  • TIEN (Tianjin) Pharmaceutical
  • TiGenix
  • Tillotts Pharma
  • Tizona Therapeutics
  • T-knife
  • Tmunity Therapeutics
  • Tonix Pharmaceuticals
  • Toyobo
  • TRACON Pharmaceuticals
  • TrakCel
  • Transgene
  • Translate Bio
  • Transporin
  • TranXenoGen
  • Trefoil Therapeutics 
  • Trellis Bioscience
  • TRIANNI
  • Trieza Therapeutics
  • Trio Pharmaceuticals
  • Triphase Accelerator
  • Tsinghua University Innovation Center for Immunotherapy 
  • TUBE Biopharmaceuticals
  • TxCell (Acquired by Sangamo Therapeutics)
  • U.S. Department of Defense
  • U.S. Government 
  • UGA Biopharma
  • UK Cystic Fibrosis Gene Therapy Consortium (GTC)
  • UK Government
  • Ultragenyx Pharmaceutical
  • University College London (UCL)
  • University of Aberdeen
  • University of Birmingham 
  • University of California
  • University of Illinois
  • University of Leeds
  • University of Pennsylvania
  • University of Queensland
  • University of Sheffield
  • University of Tokyo 
  • STUNS Life Science
  • Vaccines Manufacturing and Innovation Centre (VMIC)
  • Vaccitech 
  • Valerius Biopharma
  • Valneva 
  • Vaxart
  • VBi Therapeutics
  • VBI Vaccines
  • Vectron Biosolutions
  • Vetter Pharma
  • VGXI
  • Vibalogics
  • VIDO-InterVac
  • Vigene Biosciences
  • Vineti
  • Virovek
  • Viscofan
  • Voyager Therapeutics
  • Vipassana Research Institute (VRI) 
  • VTT Technical Research Centre of Finland 
  • Wacker Biotech
  • Waisman Biomanufacturing
  • West Biotherapy
  • WIL Research
  • Wistar Institute
  • WuXi AppTec
  • WuXi Biologics
  • Wuxi Griffin
  • Xbrane Biopharma
  • Xellbiogene
  • XL-protein 
  • Xpress Biologics
  • Yposkesi
  • Yuhan
  • Zealand Pharma 
  • Zelluna Immunotherapy
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Teruisi Pharmaceutical
  • Zhittya Genesis Medicine 
  • Ziopharm Oncology
  • Zumutor Biologics
  • Zymeworks
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll